I noticed that the CEO of NeuroDerm will be a presenter to a conference in New York at 8:30 AM on the 10th of Decembeer. I'm glad to see that. NeuroDerm needs to do a better job telliing its story as the stock does not reflect its true value, in my opinion. I believe the market is simply looking for near term catalysts to move the stock forward and are likely impatience with the 2018 goal of bringing therapies to market. Still, this is biotech and realistically time is a factor. We will be listening.